Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Fate of intrastromal injected adipose-derived mesenchymal stem cell and its effects on corneal nerve regeneration: An in vivo confocal microscopy study.

Tsai CY., Yang SC., Huang WL., Hou YT., Klochkov V., Chen MY.

Animal Study on Chronic Wound, published in Exp Eye Res (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Exp Eye Res (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41713764
DOI
10.1016/j.exer.2026.110931

Abstract (original English)

Corneal nerve damage reduces corneal sensitivity and compromises ocular surface health. This study investigated the fate of adipose-derived mesenchymal stem cells (AD-MSCs) following intrastromal injection and evaluated their effects on nerve regeneration in a rabbit model of corneal nerve injury. AD-MSCs were first characterized for MSC surface markers using immunocytochemistry staining (IHC), as well as for multipotency with trilineage and neurogenic differentiation assays. The cells expressed CD73, CD90, and CD105, and successfully differentiated into chondrogenic, osteogenic, adipogenic, and neurogenic lineages. A rabbit corneal nerve injury model was created by epithelial debridement. AD-MSCs were detectable in the central cornea up to 3 days post-injection based on in vivo confocal microscopy (IVCM) and H&E staining. TUNEL staining revealed apoptotic cells as early as 0 h after injection, indicating rapid apoptosis despite the persistence of cellular remnants for several days. MSC markers (CD73, CD90, CD105) and NGF were detected in the stroma from 0 h to day 3, and NGF was positive at the epithelium on day 28. Epithelial wound healing did not differ between AD-MSC-treated eyes and controls. However, AD-MSC injection accelerated corneal nerve regeneration, with earlier recovery observed at day 14 compared with day 21 in controls, as assessed by IVCM. Immunohistochemistry

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsRabbitsMicroscopy, ConfocalNerve RegenerationMesenchymal Stem Cell TransplantationMesenchymal Stem CellsCorneal StromaDisease Models, AnimalIn Situ Nick-End LabelingAdipose Tissue

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research